Obesity and multiple myeloma

Energy Balance and Hematologic Malignancies

Volumn , Issue , 2012, Pages 71-95

  Beason, Tracey ^a   Colditz, Graham ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84977966661     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-2403-1_4     Document Type: Chapter

References (129)

1. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91(3):421-430
2. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Br Med J 335(7630):1134
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625-1638
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569-578
5. Wolin KY, Carson K, Colditz GA (2010) Obesity and cancer. Oncologist 15(6):556-565
6. Adams TD, Gress RE, Smith SC, et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357(8):753-761
7. Sjostrom L, Narbro K, Sjostrom CD, et al (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8):741-752
8. Lichtman MA (2010) Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 15(10):1083-1101
9. International Agency for Research on Cancer (2002) Weight control and physical activity, vol.6 International Agency for Research on Cancer, Lyon
10. Wolin KY, Yan Y, Colditz GA (2011) Physical activity and risk of colon adenoma: a metaanalysis. Br J Cancer 104(5):882-885
11. Wolin KY, Yan Y, Colditz GA, Lee IM (2009) Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 100(4):611-616
12. Fair AM, Montgomery K (2009) Energy balance, physical activity, and cancer risk. Methods Mol Biol 472:57-88
13. McTiernan A (2008) Mechanisms linking physical activity with cancer. Nat Rev Cancer 8(3):205-211
14. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA (2007) Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 16(7):1474-1478
15. Wolf A, Hunter D, Colditz GA, et al (1994) Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 23:991-999
16. Chasan-Taber S, Rimm EB, Stampfer MJ, et al (1996) Reproducibility and validity of a selfadministered physical activity questionnaire for male health professionals. Epidemiology 7:81-86
17. Khan MM, Mori M, Sakauchi F, Matsuo K, Ozasa K, Tamakoshi A (2006) Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev 7(4):575-581
18. Kyle RA, Rajkumar SV (2007) Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 20(4):637-664
19. North Dakota Cancer Registry (2007) Cancer fact sheet multiple myeloma. North Dakota Department of Health, Bismarck
20. Alexander DD, Mink PJ, Adami HO, et al (2007) Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120(Suppl 12):40-61
21. Kumar S (2010) Multiple myeloma-current issues and controversies. Cancer Treat Rev 36(Suppl 2):S3-11
22. Brenner H, Gondos A, Pulte D (2009) Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 94(2):270-275
23. Altekreuse SFKC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER cancer statistics review, 1975-2007. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2007/ , based on November 2009 SSEER data submission, posted to the SEER Web site
24. Blade J, Rosinol L, Cibeira MT, de Larrea CF (2008) Pathogenesis and progression of monoclonal gammopathy of undetermined signifi cance. Leukemia 22(9):1651-1657
25. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA (2010) Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28(4):690-697
26. Pettersson T, Konttinen YT (2010) Amyloidosis-recent developments. Semin Arthritis Rheum 39(5):356-368
27. Louw VJ, Webb MJ (2010) Prognosis and treatment of Waldenstrom's macroglobulinemia. Transfus Apher Sci 42(2):193-197
28. Vijay A, Gertz MA (2007) Waldenstrom macroglobulinemia. Blood 109(12):5096-5103
29. Henry T, Fonseca R (2007) Genomics and proteomics in multiple myeloma and Waldenstrom macroglobulinemia. Curr Opin Hematol 14(4):369-374
30. Gertz MA, Fonseca R, Rajkumar SV (2000) Waldenstrom's macroglobulinemia. Oncologist 5(1):63-67
31. Nau KC, Lewis WD (2008) Multiple myeloma: diagnosis and treatment. Am Fam Physician 78(7):853-859
32. Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD (2001) Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 93(19): 1479-1483
33. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K (2006) Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 42(11):1661-1670
34. Coleman EA, Lynch H, Enderlin C, et al (2009) Initial report of a family registry of multiple myeloma. Cancer Nurs 32(6):456-464
35. McDuffi e HH, Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA (2009) Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects. BMC Cancer 9:70
36. Waxman AJ, Mink PJ, Devesa SS, et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116(25):5501-5506
37. Landgren O, Weiss BM (2009) Patterns of monoclonal gammopathy of undetermined signifi -cance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23(10):1691-1697
38. Kyle RA, Gertz MA, Witzig TE, et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21-33
39. (2009) StatBite: Multiple myeloma and African Americans: higher incidence but fewer autologous stem cell transplants. J Natl Cancer Inst 101(23):1610
40. Polednak AP (1994) Trends in cancer incidence in Connecticut, 1935-1991. Cancer 74(10):2863-2872
41. Devesa SS, Silverman DT, Young JL Jr, et al (1987) Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 79(4):701-770
42. National Cancer Institute (1975-2007) Surveillance epidemiology and end results (SEER) program. Incidence. National Cancer Institute, Bethesda, MD
43. Friedman GD, Herrinton LJ (1994) Obesity and multiple myeloma. Cancer Causes Control 5(5):479-483
44. Brown LM, Gridley G, Pottern LM, et al (2001) Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control 12(2):117-125
45. Blair CK, Cerhan JR, Folsom AR, Ross JA (2005) Anthropometric characteristics and risk of multiple myeloma. Epidemiology 16(5):691-694
46. MacInnis RJ, English DR, Hopper JL, Giles GG (2005) Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst 97(15):1154-1157
47. Oh SW, Yoon YS, Shin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic fi ndings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23(21):4742-4754
48. Engeland A, Tretli S, Hansen S, Bjorge T (2007) Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol 165(1):44-52
49. Fernberg P, Odenbro A, Bellocco R, et al (2007) Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res 67(12):5983-5986
50. Britton JA, Khan AE, Rohrmann S, et al (2008) Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica 93(11):1666-1677
51. Pylypchuk RD, Schouten LJ, Goldbohm RA, Schouten HC, Van Den Brandt PA (2009) Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol 170(3):297-307
52. Soderberg KC, Kaprio J, Verkasalo PK, et al (2009) Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. Eur J Cancer 45(7): 1232-1238
53. De Roos AJ, Ulrich CM, Ray RM, et al (2010) Intentional weight loss and risk of lymphohematopoietic cancers. Cancer Causes Control 21(2):223-236
54. Kanda J, Matsuo K, Inoue M, et al (2010) Association of anthropometric characteristics with the risk of malignant lymphoma and plasma cell myeloma in a Japanese population: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 19(6):1623-1631
55. Lu Y, Sullivan-Halley J, Henderson KD, et al (2010) Anthropometric characteristics and multiple myeloma risk. Epidemiology 21(2):272-273
56. Troy J, Hartge P, Weissfeld J, et al (2010) The relationship between anthropometry, cigarette smoking, alcohol consumption and non-hodgkin lymphoma in the PLCO trial. Am J Epidemiol 171(12):1270-1281
57. Wallin A, Larsson SC (2011) Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer 47(11):1606-1615
58. Must A, Willett WC, Dietz WH (1993) Remote recall of childhood height, weight, and body build by elderly subjects. Am J Epidemiol 138(1):56-64
59. Baer HJ, Tworoger SS, Hankinson SE, Willett WC (2010) Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 171(11):1183-1194
60. Landgren O, Rajkumar SV, Pfeiffer RM, et al (2010) Obesity is associated with an increased risk of monoclonal gammopathy of undetermined signifi cance among black and white women. Blood 116(7):1056-1059
61. Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60(8):1101-1107
62. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28(1):20-47
63. Roberts DL, Dive C, Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61:301-316
64. Hankinson SE, Willett WC, Colditz GA, et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393-1396
65. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76(9):1115-1118
66. Ma J, Pollak MN, Giovannucci E, et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91(7):620-625
67. Chen W, Wang S, Tian T, et al (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17(12):1668-1675
68. Rinaldi S, Cleveland R, Norat T, et al (2010) Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 126(7):1702-1715
69. Birmann BM, Tamimi RM, Giovannucci E, et al (2009) Insulin-like growth factor-1-and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 18(1):282-288
70. Berenson JR, Sjak-Shie NN, Vescio RA (2000) The role of human and viral cytokines in the pathogenesis of multiple myeloma. Semin Cancer Biol 10(5):383-391
71. German AJ, Ryan VH, German AC, Wood IS, Trayhurn P (2010) Obesity, its associated disorders and the role of infl ammatory adipokines in companion animals. Vet J 185(1):4-9
72. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in infl ammation and metabolic disease. Nat Rev Immunol 11(2):85-97
73. Rose DP (1997) Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 66(6 Suppl):1513S-1522S
74. Rose DP, Connolly JM (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83(3):217-244
75. Rose DP, Connolly JM (1997) Dietary fat and breast cancer metastasis by human tumor xenografts. Breast Cancer Res Treat 46(2-3):225-237
76. Legakis I, Syrigos K (2010) Obesity modulation-the role in carcinogenesis. Anticancer Agents Med Chem 10(6):481-490
77. Mouzaki A, Panagoulias I, Dervilli Z, et al (2009) Expression patterns of leptin receptor (OBR) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. Cytokine 48(3):203-211
78. Reseland JE, Reppe S, Olstad OK, et al (2009) Abnormal adipokine levels and leptin-induced changes in gene expression profi les in multiple myeloma. Eur J Haematol 83(5):460-470
79. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28(3):241-244
80. Dalamaga M, Karmaniolas K, Panagiotou A, et al (2009) Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 20(2):193-199
81. Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94(9):1221-1225
82. Housa D, Housova J, Vernerova Z, Haluzik M (2006) Adipocytokines and cancer. Physiol Res 55(3):233-244
83. Petridou E, Mantzoros C, Dessypris N, et al (2003) Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 88(3):993-997
84. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D (2006) Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94(1):156-160
85. Mantzoros C, Petridou E, Dessypris N, et al (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89(3):1102-1107
86. Wei EK, Giovannucci E, Selhub J, Fuchs CS, Hankinson SE, Ma J (2005) Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst 97(9):684-692
87. Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, infl ammation and immunity. Nat Rev Immunol 6(10):772-783
88. Wozniak SE, Gee LL, Wachtel MS, Frezza EE (2009) Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 54(9):1847-1856
89. Klein B, Zhang XG, Lu ZY, Bataille R (1995) Interleukin-6 in human multiple myeloma. Blood 85(4):863-872
90. Gado K, Domjan G, Hegyesi H, Falus A (2000) Role of Interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24(4):195-209
91. Cozen W, Gebregziabher M, Conti DV, et al (2006) Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15(11):2285-2291
92. Tzanavari T, Giannogonas P, Karalis KP (2010) TNF-alpha and obesity. Curr Dir Autoimmun 11:145-156
93. Hideshima T, Podar K, Chauhan D, Anderson KC (2005) Cytokines and signal transduction. Best Pract Res Clin Haematol 18(4):509-524
94. Christoulas D, Terpos E, Dimopoulos MA (2009) Pathogenesis and management of myeloma bone disease. Expert Rev Hematol 2(4):385-398
95. Baker RG, Hayden MS, Ghosh S (2011) NF-kappaB, infl ammation, and metabolic disease. Cell Metab 13(1):11-22
96. Oancea M, Mani A, Hussein MA, Almasan A (2004) Apoptosis of multiple myeloma. Int J Hematol 80(3):224-231
97. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR (2008) NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 15(4):391-399
98. Choi SJ, Cruz JC, Craig F, et al (2000) Macrophage infl ammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96(2):671-675
99. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY (2003) Macrophage infl ammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101(9):3568-3573
100. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296-303
101. Liu X, Tang Z, Zou P (2000) Bcl-1 rearrangement and cyclin D1 protein expression in multiple myeloma precursor cells. J Tongji Med Univ 20(2):128-131, 136
102. Demchenko Y, Glebov O, Zingone A, Keats J, Bergsagel P, Kuehl W (2010) Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115(17):3541-3552
103. Klein B (2010) Positioning NK-kappaB in multiple myeloma. Blood 115(17):3422-3424
104. Bernard M, Bancos S, Sime P, Phipps R (2008) Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 14:2051-2060
105. Ladetto M, Vallet S, Trojan A, et al (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105(12): 4784-4791
106. Kawano M, Hirano T, Matsuda T, et al (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332(6159):83-85
107. Bergsagel P, Kuehl W (2003) Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96-104
108. Naugler W, Karin M (2008) NF-K B and cancer-identifying the targets and mechanisms. Curr Opin Genet Dev 18:19-26
109. Chang E (2004) Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 96:305-315
110. Chang E (2010) Aspirin and other nonsteroidal anti-infl ammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer Epidemiol Biomark Prev 19:59-64
111. Flick ED, Chan KA, Bracci PM, Holly EA (2006) Use of nonsteroidal antiinfl ammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol 164(5):497-504
112. Zhang Y, Holford TR, Leaderer B, et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15(4):419-428
113. Cuzick J, Otto F, Baron J, et al (2009) Aspirin and non-steroidal anti-infl ammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501-507
114. Rothwell P, Wilson M, Elwin C, et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of fi ve randomised trials. Lancet 376(9754):1741-1750
115. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D (2006) Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15(12):2342-2347
116. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18):1860-1873
117. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046-1060
118. Durie BG, Kyle RA, Belch A, et al (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4(6):379-398
119. Higgins MJ, Fonseca R (2005) Genetics of multiple myeloma. Best Pract Res Clin Haematol 18(4):525-536
120. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA (2006) Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 47(5):803-814
121. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H (2000) The biology of multiple myeloma. J Cancer Res Clin Oncol 126(8):441-447
122. Van Marion AMW, Lokhorst HM, Van Den Tweel JG (2003) Pathology of multiple myeloma. Curr Diagn Pathol 9:322-327
123. Tonon G (2007) Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 21(6):985-1006, vii
124. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215-231
125. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71-87
126. Navarro WH (2003) Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 31(11):961-966
127. Rosner GL, Hargis JB, Hollis DR, et al (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14(11):3000-3008
128. Vogl DT, Wang T, Perez WS, et al (2011) Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 17(12):1765-1774
129. Nikolousis E, Nagra S, Paneesha S, et al (2010) Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Ann Hematol 89(11):1141-1145